Foundations of Metastatic TNBC: Biology, Prognosis, and the Treatment Paradigm
ByTiffany A. Traina, MD,Kamel Abou Hussein, MD,Neil Iyengar, MD,Irene Morae Kang, MD,Paolo Tarantino, MD,Fengting Yan, MD, PhD, FACP
Published: | Updated:
The panel grounds the discussion in the biology and natural history of metastatic triple-negative breast cancer, framing it as a high-proliferation subtype prone to rapid resistance, in which the first-line setting offers an important opportunity to influence outcomes. Panelists outline a biomarker-driven treatment algorithm stratified by PD-L1 status, germline BRCA status, and prior early-stage therapy, touching on immune checkpoint inhibition, PARP inhibitors, platinum-based chemotherapy, and the role of antibody-drug conjugates across lines of therapy.